Results of the Phase III COMPETE clinical trial show that the targeted radiotherapeutic agent [177Lu]Lu-edotreotide significantly prolonged progression-free survival in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) compared with targeted therapy with everolimus.

The U.S. Food and Drug Administration has approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED). Approval was granted to Viridian Therapeutics.

A new “tumor-on-a-chip” model is giving scientists a live look at how pancreatic cancer can recruit the body’s own immune cells to help tumors survive. Researchers say the findings, published in Biofabrication, reveal possible new targets to weaken the cancer’s defenses and make treatments work better.

A noninvasive neuromodulation technology has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for reducing a dangerous narrowing of blood vessels in the brain that can follow a brain bleed from a ruptured aneurysm.

A new Proceedings of the National Academy of Sciences (PNAS) special feature highlights the critical role of behavioral and decision sciences in U.S. governance. The publications demonstrate how psychological and economic research protect public health, consumer rights and finances across government agencies, including the FTC, SEC and FDA.